A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.

This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure.

开始日期2022-03-01

申办/合作机构

GE Healthcare Holdings, Inc.

[+2]

NCT02117115 / Completed早期临床1期IIT

Early Post-transplant Contrast-enhanced Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant period, as defined by the risk of contrast-related nephropathy or allergic reaction.

开始日期2014-06-01

申办/合作机构

Washington University School of Medicine

100 项与碘佛醇相关的临床结果

登录后查看更多信息

100 项与碘佛醇相关的转化医学

登录后查看更多信息

100 项与碘佛醇相关的专利（医药）

登录后查看更多信息

299

项与碘佛醇相关的文献（医药）

2024-11-01·VETERINARY ANAESTHESIA AND ANALGESIA

Ultrasound-guided ventral approach to the brachial plexus block in barred owls (Strix varia): a cadaveric study

Article

作者: Franzen-Klein, Dana ; Ienello, Lauren ; Byrne, Jessica ; Ahlmann-Garcia, Annette ; Tearney, Caitlin ; Wendt-Hornickle, Erin

OBJECTIVE:

To develop an ultrasound (US)-guided ventral approach to the brachial plexus (BP) and evaluate nerve anatomy and staining in barred owl cadavers.

STUDY DESIGN:

Prospective, cadaveric study.

ANIMALS:

Eleven adult male and female barred owl cadavers with a body mass of 0.43-0.98 kg.

METHODS:

Eleven frozen cadavers were thawed for 48 hours, weighed and assigned a body condition score. Ten cadavers were placed in dorsal recumbency with wings abducted. US-guided visualization of the BP was achieved by placing a 13-6 MHz linear probe over the ventral aspect of the scapulohumeral joint, parallel to the sternum. A 22 gauge, 50 mm insulated needle was advanced in-plane in a caudal-to-cranial direction. In each owl, injection targeting one BP was performed with 0.4 mL kg^-1 of a 1:1 0.5% ropivacaine and 1% methylene blue solution. Dissection was performed 15 minutes postinjection. Nerve staining was deemed successful if ≥ 1 cm of circumferential staining was achieved. The eleventh owl cadaver was injected with a 1:1 solution of 1% methylene blue and 74% ioversol contrast into both wings, and computed tomography (CT) was performed just before and 15 minutes after injection.

RESULTS:

The BP was clearly identified ultrasonographically in cadavers weighing > 0.5 kg. An injectate volume of 0.4 mL kg^-1 provided complete staining of the BP branches in all cadavers. CT scan revealed no contrast within the coelomic cavity.

CONCLUSIONS AND CLINICAL RELEVANCE:

The US-guided BP injection using a ventral approach was easily performed in barred owl cadavers weighing > 0.5 kg. The injection of 0.4 mL kg^-1 of a ropivacaine-dye solution resulted in complete staining of the BP branches in all wings, suggesting that this technique could provide analgesia for structures distal to the scapulohumeral joint. Clinical studies are necessary to confirm the safety and efficacy of this technique in barred owls and other bird species.

2024-10-01·FREE RADICAL BIOLOGY AND MEDICINE

LATS1 inhibitor and zinc supplement synergistically ameliorates contrast-induced acute kidney injury: Induction of Metallothionein-1 and suppression of tubular ferroptosis

Article

作者: Wang, Dekun ; Zhang, Yuying ; Du, Mengwei ; Zhou, Donghui ; Dou, Lin ; Xie, Shuangshuang ; Yue, Shijing ; Su, Yu ; Dai, Bo ; Tan, Xiaoyue ; Shen, Tianyu ; Mi, Xue ; Liu, Xuan

Contrast-induced acute kidney injury (CI-AKI) is a prevalent cause of renal dysfunction among hospitalized patients, yet the precise pathogenesis and effective therapeutic strategies remain elusive. In this study, we investigated the role of tubular ferroptosis in both experimental CI-AKI models and in primary tubular epithelial cells (PTECs) treated with ioversol. Using whole exome sequencing, we identified metallothioneins (MTs) as being among the most significantly downregulated genes following ioversol exposure. Our findings reveal that overexpression of Mt1 mitigates, whereas suppression of Mt-1 exacerbates, ioversol-induced tubular ferroptosis. Interestingly, the level of MTF1 (metal regulatory transcription factor 1), a principal regulator of Mt1, was found to increase in response to ioversol treatment. We further elucidated that ioversol activates LATS1 (Large tumor suppressor homolog 1), a kinase that promotes the phosphorylation and nuclear translocation of MTF1, thereby inhibiting its transcriptional activity for Mt1. Both genetic and pharmacological inhibition of LATS1 reversed the ioversol-induced suppression of Mt-1. From a therapeutic perspective, the LATS1 inhibitor TDI-011536, in combination with zinc acetate, was administered to a rodent model of CI-AKI. Our data indicate that this combination synergistically upregulates Mt1 expression and provides protection against contrast media-induced tubular ferroptosis. In summary, our study demonstrates that the reduction of Mt-1 contributes to tubular ferroptosis associated with CI-AKI. We show that contrast media activate LATS1, which in turn suppresses the transcriptional activity of MTF1 for Mt1. Herein, the combination of zinc acetate and a LATS1 inhibitor emerges as a potential therapeutic approach for the treatment of CI-AKI.

2024-10-01·EUROPEAN JOURNAL OF RADIOLOGY

Impact of different concentration iodinated contrast media on pain and comfort in abdominal computed tomography

Article

作者: Zhang, Lan ; Shang, Jing ; Sun, Ying-Shi ; Zhang, Xiao-Yan ; Li, Xiao-Ting ; Li, Dan-Ni ; Sun, Yan-Xia ; You, Miao-Ning ; Tian, Xiao-Yu ; Gu, Xiao-Lei ; Sun, Nan ; Cui, Yong ; Zhang, Ke-Jin

OBJECTIVES:

To investigate whether high concentration iodinated contrast media (CM), compared with low concentration CM, could reduce pain and discomfort levels in patients who had level II and III venous conditions.

METHODS:

This prospective, single-center study enrolled patients who had level II and III venous conditions and underwent abdominal contrast-enhanced CT scan between July 2021 and February 2022. The venous condition to establish peripheral venous access for CM injection was graded using the Intravenous Access Scoring system, of which level II and III indicated poor venous condition and difficult venous access. Patients received iomeprol 400 in high concentration group and ioversol 320 in low group at an identical iodine delivery rate of 1.12 gI/s. The primary outcomes were pain and comfort levels. The secondary outcomes included adverse events and image quality. Patients rated pain intensity via Numerical Rating Scale and comfort level via Visual Analogue Scale with higher scores indicating higher levels of pain and discomfort. Quantitative and qualitative image assessment were compared between two groups. Continuous variables were compared using Student's t test or Mann-Whitney U test. Categorical variables were compared using χ² test, χ² test for trend or Fisher's exact test.

RESULTS:

A total of 206 patients (mean age, 60.13 ± 12.14 years; 81 males) were included with 99 in the high concentration group and 107 in the low concentration group. The high group had significantly lower pain scores (median 1 [IQR: 0-2] vs 2 (IQR 2-4), p < 0.001) and comfort scores (1 [IQR: 0-3] vs 3 [IQR: 2-5], p < 0.001) than the low group. Incidence of CM extravasation did not significantly differ (1.0 % vs 4.5 %, p = 0.214). No hypersensitivity reaction was observed. Qualitative assessment showed higher clarity scores of intrahepatic hepatic artery and portal vein in the high group. Quantitative assessment results were comparable between two groups.

CONCLUSION:

High concentration iodinated CM could lower pain intensity and improve comfort levels without comprising image quality of CT scan. High concentration CM is a preferable choice in patients with poor venous conditions during contrast-enhanced CT scan.

110

项与碘佛醇相关的新闻（医药）

2024-12-03

·摩熵医药

倍特药业拿下29亿+注射剂，4大品种同日获批！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 12月02日，据NMPA官网公示，倍特药业有4款注射剂同日获批生产并视同过评，包含碘佛醇注射液、尼莫地平注射液、卡络磺钠注射液和子公司海南倍特药业的注射用盐酸罗沙替丁醋酸酯。其中碘佛醇注射液是造影剂TOP1产品，成为公司第9款造影剂，该品种在2023年全国院内市场的销售额超29亿元。截图来源：NMPA 29亿造影剂，国内仅3家药企迎来过评碘佛醇注射液是临床广泛应用的造影剂之一，属于非离子型、低渗、水溶性且X线不透射的造影剂，主要通过血管内给药。其作用原理在于，造影剂注入血管后，能使流经的血管区域呈现不透光性，从而在X光照射下清晰显影。该产品于1988年率先获得美国FDA批准上市，1999年成功引入中国市场，2000年被纳入国家医保乙类目录，2009年更进一步升级至医保甲类目录。据摩熵医药数据库显示，碘佛醇注射液在2023年全国院内市场的销售额超29亿元，同比增长达10.69%，同时碘佛醇注射液是2023年造影剂院内TOP1品种。截图来源：摩熵医药（原药融云）全国医院销售数据库截至目前，已有5家药企获得了碘佛醇注射液的生产批文，其中包括2家进口药企及3家国内药企。在过评方面，碘佛醇注射液在国内仅江苏恒瑞医药、成都倍特药业以及上海司太立制药这3家迎来过评。截图来源：摩熵医药（原药融云）过评药品汇总数据库倍特药业在造影剂领域的产品线不断壮大，目前已有9款品种获批，2022年成都倍特药业的首款造影剂碘普罗胺注射液获批，2023年成都倍特药业拿下了碘帕醇注射液和碘克沙醇注射液。今年以来，倍特药业（含子公司）有碘佛醇注射液、钆塞酸二钠注射液、钆布醇注射液、钆特酸葡胺注射液、钆特醇注射液、钆贝葡胺注射液6个品种陆续上市，倍特药业（含子公司）的造影剂已累计有9款。截图来源：摩熵医药（原药融云）中国药品审评数据库其中钆特酸葡胺注射液、碘克沙醇注射液、碘帕醇注射液和碘普罗胺注射液4个品种均已登上2023年全国医院内销售造影剂的TOP10榜单。截图来源：摩熵医药（原药融云）全国医院销售数据库 37款品种扎堆过评，两款产品压线进入十批集采倍特药业此番成功获批的注射用盐酸罗沙替丁醋酸酯与尼莫地平注射液，均被列为第十批国家集采药品，可谓是“压线”入场。其中盐酸罗沙替丁醋酸酯是一款组胺H2受体拮抗剂，主要是治疗与胃酸分泌相关疾病的药物，临床上用于上消化道出血（由消化性溃疡，急性应激性溃疡，出血性胃炎等引起）的低危患者。近年来，注射用盐酸罗沙替丁醋酸酯销售规模持续上涨，据摩熵医药数据库显示，注射用盐酸罗沙替丁醋酸酯在2023年全国院内市场的销售额逼近10亿元。截图来源：摩熵医药（原药融云）全国医院销售数据库截至目前，国内已有四川汇宇制药、扬子江药业、海南倍特药业、瑞阳制药、江苏奥赛康药业等17家企业的注射用盐酸罗沙替丁醋酸酯过评或视同过评。截图来源：摩熵医药（原药融云）过评药品汇总数据库此外，尼莫地平注射液目前有超40家药企拥有生产批文，该品种可用于预防和治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛引起的缺血性神经损伤。在仿制药布局方面，该品种还有四川科伦药业、四川美大康佳乐药业、山东华铂凯盛生物科技等5家药企提交了4类注册仿制申请。截图来源：摩熵医药（原药融云）中国药品审评数据库 2024年至今，倍特药业（含子公司）有37款品种迎来过评，其中注射用头孢唑肟钠、呋塞米口服溶液、钆贝葡胺注射液3款品种为首家过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准医药出海申请上市核酸药物

2024-12-03

·米内网

【重磅】倍特药业大丰收！4款注射剂同日获批

精彩内容近日，国家药监局官网显示，倍特药业4款注射剂同日获批生产并视同过评，分别为卡络磺钠注射液、注射用盐酸罗沙替丁醋酸酯、碘佛醇注射液及尼莫地平注射液，其中碘佛醇注射液2023年在中国公立医疗机构终端的销售额超过30亿元，注射用盐酸罗沙替丁醋酸酯、尼莫地平注射液均为第十批集采品种。今年以来，倍特药业有31个品种获批生产并视同过评。注射用盐酸罗沙替丁醋酸酯、尼莫地平注射液均为第十批集采品种，倍特药业“压线”获得入场券。罗沙替丁是一种组胺H2受体拮抗剂，适用于上消化道出血（由消化性溃疡、急性应激性溃疡、出血性胃炎等引起）的低危患者。国内已上市的罗沙替丁制剂仅注射用盐酸罗沙替丁醋酸酯一种，该产品2022年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端的销售额超过14亿元，2023年回落至接近12亿元，2024上半年有所回升。从最新厂家竞争格局看，北京轩升制药（已过评）以约66%的市场份额领跑，哈药生物（已过评）以约23%的市场份额紧接在后，瑞阳制药（已过评）以约11%的市场份额排位第三。近年来中国公立医疗机构终端注射用盐酸罗沙替丁醋酸酯销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局国内已有17家企业的注射用盐酸罗沙替丁醋酸酯过评或视同过评，包括重庆药友制药、四川汇宇制药、扬子江药业、江苏奥赛康药业、海南倍特药业等。在第十批集采中，该产品最高采购额（首年约定采购量*最高有效申报价，下同）超过7000万元。碘佛醇注射液是一款经血管用药的非离子、低渗透、水溶性、不透射线造影剂，目前已被纳入国家医保甲类目录。含倍特药业在内，有3家国内企业的碘佛醇注射液视同过评，该产品2023年在中国公立医疗机构终端的销售额突破30亿元，2024上半年有所回落。近年来中国公立医疗机构终端碘佛醇注射液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局在造影剂领域，倍特药业已拥有9款产品的生产批文，分别为碘普罗胺注射液、碘帕醇注射液、碘克沙醇注射液、钆贝葡胺注射液、钆特酸葡胺注射液、碘佛醇注射液、钆塞酸二钠注射液、钆特醇注射液、钆布醇注射液。米内网数据显示，今年以来，倍特药业（含子公司）有1款2.2类改良型新药获批上市，为盐酸右美托咪定鼻喷雾剂，公司为国内第2家获批；此外，31个品种获批生产并视同过评，包括6个造影剂、4个心脏病治疗用药、3个高血压用药、3个糖尿病用药、2个全身用抗细菌药、2个止血药等。今年以来倍特药业获批上市的品种来源：米内网中国申报进度（MED）数据库 31个仿制药中，多个品种为国内首批上市。其中，呋塞米口服溶液为国内首仿+首家过评，钆特酸葡胺注射液、罗沙司他胶囊、钆贝葡胺注射液为第2家仿制，钆特醇注射液、酮咯酸氨丁三醇片、碘佛醇注射液、马来酸氟伏沙明片、钆塞酸二钠注射液、马来酸阿伐曲泊帕片为国产第3家等。资料来源：米内网数据库、国家药监局官网等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至12月3日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

带量采购上市批准申请上市一致性评价医药出海

2024-12-02

·药筛

国采终局，48个批文，赶上十批国采末班车

如我所料，12月2日，十批国采批文关门之日，NMPA放出158个新批文，其中48个文号在十批国采目录。阿普米斯特片，阿司匹林肠溶片、氟尿嘧啶注射液、复方聚乙二醇电解质散(Ⅲ)等品种，竞争格局变了。而对于己酮可可碱注射液、间苯三酚注射液等超级卷的产品，多一家，少一家，似乎意义也不大了。明天晚上8点，我会再发起一场直播，详细聊聊产品的竞争格局。药品名称申请人批准文号受理号阿普米司特片广东迈恒医药研发有限公司国药准字H20249508CYHS2301476阿普米司特片广东迈恒医药研发有限公司国药准字H20249509CYHS2301477阿普米司特片广东迈恒医药研发有限公司国药准字H20249510CYHS2301478阿普米司特片常州制药厂有限公司国药准字H20249591CYHS2301810阿普米司特片常州制药厂有限公司国药准字H20249592CYHS2301811阿普米司特片常州制药厂有限公司国药准字H20249593CYHS2301812阿奇霉素干混悬剂山东淄博新达制药有限公司————CYHB2450159阿司匹林肠溶片河北创健药业有限公司国药准字H20249600CYHS2302409、CYHB2401720阿昔莫司胶囊浙江高跖医药科技股份有限公司国药准字H20249501CYHS2303120氨己烯酸口服溶液用散远大医药（中国）有限公司国药准字H20249622CYHS2300027国氨溴特罗口服溶液浙江康润制药有限公司国药准字H20249464CYHS2300382氨溴特罗口服溶液浙江康润制药有限公司国药准字H20249465CYHS2300383氨溴特罗口服溶液江西仁齐制药有限公司国药准字H20249471CYHS2301066奥美沙坦酯氢氯噻嗪片宁波科尔康美诺华药业有限公司国药准字H20249578CYHS2300248玻璃酸钠滴眼液华熙生物科技股份有限公司国药准字H20249484CYHS2301663布洛芬缓释胶囊南京华兴医药科技有限公司国药准字H20249479CYHS2301450达比加群酯胶囊熙德隆药业（北京）有限公司国药准字HJ20240154JYHS2000002国达比加群酯胶囊熙德隆药业（北京）有限公司国药准字HJ20240155JYHS2000003国达比加群酯胶囊熙德隆药业（北京）有限公司国药准字HJ20240156JYHS2000006国达格列净二甲双胍缓释片（I）南京正大天晴制药有限公司国药准字H20249466CYHS2300498达格列净二甲双胍缓释片（III）南京正大天晴制药有限公司国药准字H20249467CYHS2300499达格列净片浙江华义制药有限公司国药准字H20249540CYHS2301952达格列净片浙江华义制药有限公司国药准字H20249541CYHS2301953地高辛注射液江苏联环药业股份有限公司国药准字H20249590CYHS2301735地夸磷索钠滴眼液国药集团三益药业（芜湖）有限公司国药准字H20249530CYHS2302234地诺孕素片博瑞制药（苏州）有限公司国药准字H20249468CYHS2300580碘比醇注射液重庆圣华曦药业股份有限公司国药准字H20249462CYHS2300166碘比醇注射液重庆圣华曦药业股份有限公司国药准字H20249463CYHS2300167碘佛醇注射液成都倍特药业股份有限公司国药准字H20249482CYHS2301601碘佛醇注射液成都倍特药业股份有限公司国药准字H20249483CYHS2301602恩格列净片湖南迪诺制药股份有限公司国药准字H20249556CYHS2302022二甲双胍恩格列净片（Ⅰ）杭州云柏医药科技有限公司国药准字H20249506CYHS2300814二甲双胍恩格列净片（Ⅴ）杭州云柏医药科技有限公司国药准字H20249507CYHS2300815二羟丙茶碱注射液安徽长江药业有限公司国药准字H20249517CYHS2300942非诺贝特酸胆碱缓释胶囊鲁南贝特制药有限公司国药准字H20249524CYHS2301087非诺贝特酸胆碱缓释胶囊鲁南贝特制药有限公司国药准字H20249525CYHS2301088氟比洛芬钠滴眼液武汉先路医药科技股份有限公司国药准字H20249614CYHS2200829国氟尿嘧啶注射液湖南赛隆药业（长沙）有限公司国药准字H20249674CYHS2301428氟唑帕利胶囊江苏恒瑞医药股份有限公司国药准字H20200014CXHS2400032复方醋酸钠葡萄糖注射液石家庄四药有限公司国药准字H20249560CYHS2301103复方醋酸钠葡萄糖注射液石家庄四药有限公司国药准字H20249561CYHS2301104复方聚乙二醇电解质散(Ⅲ)安徽省先锋制药有限公司国药准字H20249673CYHS2301384复方托吡卡胺滴眼液南京恒道医药科技股份有限公司国药准字H20249621CYHS2201645国钆特酸葡胺注射液山东新时代药业有限公司国药准字H20249640CYHS2301815钆特酸葡胺注射液山东新时代药业有限公司国药准字H20249641CYHS2301816钆特酸葡胺注射液山东新时代药业有限公司国药准字H20249642CYHS2301817钆特酸葡胺注射液上海礼易医药科技有限公司国药准字HJ20240158JYHS2300001枸橼酸坦度螺酮片山东京卫制药有限公司国药准字H20249656CYHS2302793枸橼酸坦度螺酮片山东京卫制药有限公司国药准字H20249657CYHS2302794己酮可可碱注射液江苏慧聚药业股份有限公司国药准字H20249505CYHS2300543甲磺酸阿帕替尼片江苏恒瑞医药股份有限公司国药准字H20140103CXHS2400030甲磺酸阿帕替尼片江苏恒瑞医药股份有限公司国药准字H20140104CXHS2400031甲磺酸仑伐替尼胶囊江苏康缘药业股份有限公司国药准字H20249469CYHS2300794甲磺酸沙非胺片精鼎医药研究开发（上海）有限公司国药准字HJ20240142JXHS2200034国甲磺酸沙非胺片精鼎医药研究开发（上海）有限公司国药准字HJ20240143JXHS2200035国甲硫酸新斯的明注射液东阳祥昇医药科技有限公司国药准字H20249616CYHS2302054甲硫酸新斯的明注射液东阳祥昇医药科技有限公司国药准字H20249617CYHS2302055间苯三酚口崩片湖南先施制药有限公司国药准字H20249511CYHS2301727间苯三酚口崩片浙江高跖医药科技股份有限公司国药准字H20249554CYHS2301786间苯三酚注射液湖北午时医药研究院有限公司国药准字H20249634CYHS2301535间苯三酚注射液福建天泉药业股份有限公司国药准字H20249608CYHS2302371精氨酸培哚普利片杭州仟源保灵药业有限公司国药准字H20249513CYHS2302478精氨酸培哚普利片杭州仟源保灵药业有限公司国药准字H20249514CYHS2302479聚乙烯醇滴眼液上海阿尔福斯医药科技有限公司国药准字H20249470CYHS2300992卡贝缩宫素注射液成都诺和晟鸿生物制药有限公司国药准字H20249486CYHS2301732卡络磺钠注射液成都倍特药业股份有限公司国药准字H20249456CYHS2201630国卡络磺钠注射液成都倍特药业股份有限公司国药准字H20249457CYHS2201631国卡络磺钠注射液成都倍特药业股份有限公司国药准字H20249458CYHS2201632国卡前列素氨丁三醇注射液北京仁众药业有限公司国药准字H20249651CYHS2302262利奈唑胺干混悬剂广州一品红制药有限公司国药准字H20249523CYHS2202052国磷酸奥司他韦干混悬剂广东万方药业科技有限公司国药准字H20249619CYHS2200236国磷酸奥司他韦胶囊遂成药业股份有限公司国药准字H20249520CYHS2400585磷酸奥司他韦胶囊遂成药业股份有限公司国药准字H20249521CYHS2400586硫酸阿米卡星注射液宁波大红鹰药业股份有限公司CYHB2450025硫酸阿米卡星注射液宁波大红鹰药业股份有限公司CYHB2450026硫酸镁钠钾口服用浓溶液丽珠集团丽珠制药厂国药准字H20249519CYHS2301893硫酸羟氯喹片西安海欣制药有限公司国药准字H20249532CYHS2302632硫酸特布他林口服溶液成都利尔药业有限公司国药准字H20249476CYHS2301326硫酸特布他林口服溶液成都利尔药业有限公司国药准字H20249477CYHS2301327铝碳酸镁咀嚼片江右制药（常德）有限公司国药准字H20249492CYHS2302099氯化钾颗粒山西普德药业有限公司国药准字H20249672CYHS2301126氯化钾注射液石药银湖制药有限公司————CYHB2350676氯化钾注射液南京恩泰医药科技有限公司国药准字H20249553CYHS2301547氯化钾注射液成都欣捷高新技术开发股份有限公司国药准字H20249480CYHS2301578氯化钾注射液成都米子生物医药科技有限公司国药准字H20249481CYHS2301596氯化钾注射液河南群益医药科技开发有限公司国药准字H20249638CYHS2301723、CYHB2401582氯化钾注射液黑龙江博宇制药有限公司国药准字H20249675CYHS2302209氯雷他定糖浆合肥远志医药科技开发有限公司国药准字H20249491CYHS2302039氯沙坦钾氢氯噻嗪片宁波科尔康美诺华药业有限公司国药准字H20249485CYHS2301692马来酸阿伐曲泊帕片山东良福制药有限公司国药准字H20249493CYHS2302166马来酸阿法替尼片甘肃兰药药业有限公司国药准字H20249612CYHS2101073国马来酸阿法替尼片甘肃兰药药业有限公司国药准字H20249613CYHS2101074国马来酸氟伏沙明片安徽省先锋制药有限公司国药准字H20249543CYHS2302390马来酸氟伏沙明片安徽省先锋制药有限公司国药准字H20249544CYHS2302391吗啉硝唑氯化钠注射液成都国为生物医药有限公司国药准字H20249460CYHS2202045国尼可地尔片东阳祥昇医药科技有限公司国药准字H20249574CYHS2302379尼莫地平注射液成都倍特药业股份有限公司国药准字H20249601CYHS2302461帕拉米韦注射液湖北民康药业集团有限公司国药准字H20249474CYHS2301271帕拉米韦注射液山西阳和医药技术有限公司国药准字H20249584CYHS2301504哌柏西利片南京正大天晴制药有限公司国药准字H20249528CYHS2302060哌柏西利片南京正大天晴制药有限公司国药准字H20249529CYHS2302061哌柏西利片石药集团欧意药业有限公司国药准字H20249515CYHS2400665培哚普利氨氯地平片(Ⅲ)广州市联瑞制药有限公司国药准字H20249535CYHS2300948、CYHB2401072苹果酸舒尼替尼胶囊瑞迪博士（北京）药业有限公司国药准字HJ20240157JYHS2200003国泊沙康唑肠溶片北京金康驰医药投资有限公司国药准字HJ20240139JYHS2200053国普拉洛芬滴眼液圣嘉（滨海）生物医药科技有限公司国药准字H20249494CYHS2302440氢溴酸伏硫西汀片杭州和康药业有限公司国药准字H20249594CYHS2301881屈螺酮炔雌醇片南通联亚药业股份有限公司国药准字H20249620CYHS2200411国乳果糖口服溶液黑龙江中桂制药有限公司国药准字H20249558CYHS2300689乳果糖口服溶液黑龙江中桂制药有限公司国药准字H20249559CYHS2300690乳果糖口服溶液海南斯达制药有限公司国药准字H20249475CYHS2301323瑞巴派特片北京金城泰尔制药有限公司国药准字H20249489CYHS2301916瑞巴派特片苏州旺山旺水生物医药股份有限公司国药准字H20249490CYHS2301934舒更葡糖钠注射液中国大冢制药有限公司国药准字H20249534CYHS2300867舒更葡糖钠注射液弘和制药有限公司国药准字H20249568CYHS2300937羧甲司坦口服溶液北京康晟百春生物科技有限公司国药准字H20249533CYHS2202114国缩宫素注射液安徽百奥药业有限公司国药准字H20249472CYHS2301105碳酸司维拉姆片国药集团致君（深圳）坪山制药有限公司国药准字H20249635CYHS2301555替米沙坦氨氯地平片康缘华威医药有限公司国药准字H20249563CYHS2301967替米沙坦氨氯地平片山西德元堂药业有限公司国药准字H20249564CYHS2302154酮咯酸氨丁三醇注射液福建天泉药业股份有限公司国药准字H20249527CYHS2301620托拉塞米注射液海南斯达制药有限公司国药准字H20249580CYHS2301008托拉塞米注射液海南斯达制药有限公司国药准字H20249581CYHS2301009吸入用乙酰半胱氨酸溶液陕西丽彩药业有限公司国药准字H20249497CYHS2302648西格列汀二甲双胍片（II）浙江英格莱制药有限公司国药准字H20249536CYHS2301433腺苷注射液华夏生生药业（北京）有限公司国药准字H20249455CYHS2201223国腺苷注射液北京布霖生物科技有限公司国药准字H20249461CYHS2202062国硝酸异山梨酯注射液安徽誉恒生物科技有限公司国药准字H20249499CYHS2302801亚叶酸钙注射液石家庄荣雾迪医药科技有限公司国药准字H20249531CYHS2302359盐酸艾司洛尔注射液湖南赛隆药业（长沙）有限公司国药准字H20249552CYHS2301503盐酸丙卡特罗口服溶液江苏万高药业股份有限公司国药准字H20249488CYHS2301818盐酸多奈哌齐片泰荣（福建）药业有限公司国药准字H20249618CYHS2101184国盐酸多奈哌齐片保定天浩制药有限公司国药准字H20249669CYHS2101423国盐酸多奈哌齐片宝龙药业有限公司国药准字H20249670CYHS2201419国盐酸多柔比星脂质体注射液诺桥制药（成都）有限责任公司国药准字H20249633CYHS2301507、CYHB2401350盐酸甲哌卡因注射液济南辰欣医药科技有限公司国药准字H20249473CYHS2301195盐酸莫西沙星氯化钠注射液河北凯威恒诚制药有限公司国药准字H20249459CYHS2201999国盐酸异丙肾上腺素注射液成都米子生物医药科技有限公司国药准字H20249512CYHS2302299氧氟沙星滴耳液山东光明药业有限公司国药准字H20249487CYHS2301752伊布替尼胶囊山东齐都药业有限公司国药准字H20249566CYHS2300103、CYHB2401322依达拉奉右莰醇舌下片先声药业有限公司国药准字H20240041CXHS2300058依折麦布片江苏德源药业股份有限公司国药准字H20249498CYHS2302773乙酰半胱氨酸泡腾片嘉亨（珠海横琴）医药科技有限公司国药准字H20249496CYHS2302616、CYHB2401400吲哚布芬片北京诚济制药股份有限公司国药准字H20249478CYHS2301349重酒石酸间羟胺注射液河南蓝图制药有限公司国药准字H20249671CYHS2300889重酒石酸去甲肾上腺素注射液武汉久安药业有限公司国药准字H20249676CYHS2302220注射用丁二磺酸腺苷蛋氨酸重庆药友制药有限责任公司国药准字H20249503CYHS2300037国注射用尼可地尔重庆德诚永道医药有限公司国药准字H20249615CYHS2301328注射用尼可地尔海南皇隆制药股份有限公司国药准字H20249595CYHS2302094注射用尼可地尔海南皇隆制药股份有限公司国药准字H20249596CYHS2302095注射用亚胺西瑞默沙东研发（中国）有限公司国药准字HJ20240140JXHS2300065注射用亚胺西瑞默沙东研发（中国）有限公司国药准字HJ20240141JXHS2300066注射用盐酸多西环素海南普利制药股份有限公司国药准字H20249576CYHS2201635国注射用盐酸多西环素海南普利制药股份有限公司国药准字H20249577CYHS2201636国注射用盐酸罗沙替丁醋酸酯海南倍特药业有限公司国药准字H20249526CYHS2301212左卡尼汀口服溶液江苏百奥信康医药科技有限公司国药准字H20249495CYHS2302472ω-3脂肪酸乙酯90软胶囊扬子江药业集团有限公司国药准字H20249504CYHS2300357 使用”摩熵药筛“小程序，可以查询国采产品的竞争、价格、市场销售数据。十批国采分享微信群已建，欢迎企业和代理商入群，对接资源。加客服小狐微信，拉你入群！

申请上市带量采购

100 项与碘佛醇相关的药物交易

登录后查看更多信息